- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02889224
In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man (VISECA)
Working hypothesis: the interactions between the endogenous endocannabinoïds (ECS) - and cortisol, the end product of the Hypothalamo-Pituitary-Adrenal (HPA) axis may play a role in the pathophysiology of Cushing's syndrome.
The investigators speculate that:
- acute or chronic variations in plasma cortisol may induce changes in the activity of the ECS
- that there is a circadian rhythm of the ECS driven by the rythm of plasma cortisol
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study aim to identify the relationship between the ECS and the HPA axis in humans with a main objective to assess if Cushing's syndrome induces changes in the ECS activity.
For this purpose:
- the investigors will compare plasma levels of ECS between obese controls and patients with Cushing's syndrome
- the investigors will compare plasma levels of ECS in patients with Cushing's syndrome before and immediately after curative surgery
- the investigors will compare plasma levels of ECS in patients with hypoadrenalism before and after the intake of substitutive doses of hydrocortisone
- the investigors will evaluate the plasma levels of ECS during a short synacthen test in healthy subjects.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Pessac, France, 33600
- Service d'Endocrinologie, Hopital Haut-Leveque
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For all patients groups:
- Age ≥ 18,
- Social security.
" Hypercortisolism " group:
- 18 < BMI < 40 kg/m2,
- Cushing's syndrome in front of :
- impaired 1 mg dexamethasone test (08:00 A.M. cortisol > 50 nmol/L)
- qualitative and quantitative disrupted circadian rhythm of cortisol with increased plasma concentrations
- free urinary cortisol upper normal range (90 µg/24H),
- Hypercortisolism that can be treated with surgery (adrenal adenoma treated with adrenalectomy or Cushing disease treated with pituitary surgery).
" Obese " group:
- Obese patients: 30 < BMI < 40 kg/m2,
- Normal HPA axis function:
- 08:00 A.M. cortisol > 250 nmol/L and peak above 550 nmol/L after 1 mg SST,
- Normal 24H free urinary cortisol and dexamethasone test. " Control " group:
- Lean or overweight patients (18 < BMI < 30 kg/m2),
- Non cortisol secreting pituitary or adrenal tumor,
- Patient in whom a biological evaluation of the HPA axis is recommended.
" Hydrocortisone " group:
- Lean or overweight patients (18 < BMI < 30 kg/m2),
- Primary or secondary adrenal insufficiency,
- With a need for hydrocortisone supplementation.
Exclusion Criteria:
- Patients with eating disorders, major depressive disorders or psychiatric disorders other than Cushing's syndrome,
- Cannabis consumption, alcoholism or drug addiction,
- Active smoking,
- cortisone treatment other than hydrocortisone,
- Pregnancy or feeding,
- Surgery for obesity,
- Incapability,
- Pathology that is life-threatening in the short term,
- Any situation that interfere with study or is risked for patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Obese
Subjects with BMI between 30 - 40 kg/m2 and no alteration of corticotrope axis.
|
|
Experimental: Hypercortisolism
Subject with BMI between 18 - 40 kg/m2 and presenting a hypercortisolism defined by HAS (Haute Autorité de Santé).
|
|
Experimental: Hydrocortisone
Subject with BMI between 18 - 30 kg/m2 and with adrenal or corticotrope failure
|
|
Experimental: Control
Subject with BMI between 18 - 30 kg/m2 and with a pituitary or adrenal tumor without effect on corticotrope axis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fluctuations of 2-AG (2-arachidonoyl-Glycérol) plasma concentration in relationship to cortisol plasma concentration in obese arm compare to hypercortisolism arm.
Time Frame: Baseline
|
The primary outcome will be assessed by a measurement of plasma concentration of 2-AG during the circadian rhythm of ACTH/cortisol.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of plasma concentration of AEA (Anandamide), OEA (Oleoyl-EthanolAmide) and PEA (Palmitoyl-EthanolAmide) endocannabinoïds associated with variations of plasma cortisol in hypercortisolism arm
Time Frame: Baseline and day 6
|
The secondary outcome wille be assessed by a measurement of plasma concentration of AEA, OEA and PEA during the circadian rhythm of ACTH/cortisol.
|
Baseline and day 6
|
Measurement of plasma concentration of AEA (Anandamide), OEA (Oleoyl-EthanolAmide) and PEA (Palmitoyl-EthanolAmide) endocannabinoïds associated with variations of plasma cortisol in hydrocortisone arm
Time Frame: Baseline
|
Measurement of plasma concentration of AEA, OEA and PEA on 07:30 A.M. ± 1 hour (fasting), 08:00 A.M. ± 1 hour (fasting), 09:00 A.M. ± 1 hour, 10:00 A.M. ± 1 hour, 04:00 P.M. ± 1 hour
|
Baseline
|
Measurement of plasma concentration of AEA (Anandamide), OEA (Oleoyl-EthanolAmide) and PEA (Palmitoyl-EthanolAmide) endocannabinoïds in control arm who have no cortisol production problem.
Time Frame: Baseline
|
Measurement of plasma concentration of AEA, OEA and PEA during the circadian rhythm of ACTH/cortisol
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Paul PEREZ, MD, University Hospital, Bordeaux
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2010/34
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cushing's Syndrome
-
RECORDATI GROUPRecruitingEndogenous Cushing's SyndromeUnited States, Germany, France
-
Corcept TherapeuticsCompleted
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Bulgaria, Denmark, France, Greece, Hungary, Israel, Italy, Netherlands, Poland, Romania, Spain
-
Wuerzburg University HospitalCompletedEndogenous Cushing's SyndromeGermany
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Serbia, Denmark, Italy, Spain, Poland, Belgium, Bulgaria, Canada, Czechia, France, Germany, Israel, Netherlands, Turkey
-
Andrea M. IsidoriCompletedCushing's Syndrome CardiomyopathyItaly
-
Sparrow PharmaceuticalsRecruitingAutonomous Cortisol Secretion (ACS) | ACTH-Independent Cushing Syndrome | ACTH-Independent Adrenal Cushing Syndrome, SomaticUnited States, United Kingdom, France, Romania
-
Sheffield Teaching Hospitals NHS Foundation TrustHRA PharmaCompleted
-
University Hospital, Clermont-FerrandUnité de recherche GReD CNRS UMR6293 / InsermRecruitingOsteoporosis in Cushing's Syndrome | Osteoporosis in Post-menopausal WomenFrance
-
HRA PharmaRecruitingCushing SyndromeSweden, France, Croatia, Spain
Clinical Trials on Control
-
Claudia M. WittCompleted
-
University of California, San FranciscoWithdrawn
-
The George InstituteChanghai Hospital; University of CalgaryNot yet recruiting
-
Universidad Nacional de Educación a DistanciaMinisterio de Economía y Competitividad, SpainUnknownChronic Pain | FibromyalgiaSpain
-
University of California, Los AngelesThe National Council on Aging; City of Los Angeles Department of Aging; Los Angeles...Completed
-
Queen's University, BelfastPublic Health Agency, Health and Social Care Research and Development; Tiny...Completed
-
National Taiwan University HospitalEnrolling by invitationCognitive Function | Atrial Fibrillation, PersistentTaiwan
-
Takeshi MorimotoUniversity of the RyukyusActive, not recruitingCoronary Artery Disease | Hypertension | Type 2 Diabetes | DyslipidemiaJapan
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Vanderbilt University Medical CenterCompleted